TIAP, Evotec, AmorChem invest in Sinai Health newborn skin disease project
Toronto Innovation Acceleration Partners, Evotec SE and Canadian life sciences venture capital firm AmorChem have together invested C$1.75 million in the Netherton Syndrome project at Toronto-based Sinai Health.
